Adjuvant chemohormonal therapy of high risk XXXX . Ten year results.

@entity1 @entity632 @entity263 @entity5 @entity1138 @entity342 @entity1486 @entity5713
BACKGROUND: @entity1 with @entity263 have poor cure rates. The authors sought to improve the relapse free, @entity5 specific survival of these @entity1 by adding chemohormonal therapy to radiation. METHODS: Twenty-five @entity1 with clinical Stage III positive seminal vesicles or positive nodes received six courses of @entity5713 , @entity632 , and @entity1138 with simultaneous radiation and permanent @entity342 deprivation. @entity1486 (PSA) testing was the sole criterion for relapse. Median followup was 10.5 years. RESULTS: Treatment was well tolerated. @entity1 received 91-95% of each drug and all planned radiation. At 10 years the cumulative relapse free rate determined by continuously undetectable PSA levels was 73%, and the cumulative @entity5 specific survival was 81%. Of node-positive @entity1 , 82% were relapse-free at 10 years. CONCLUSIONS: The addition of chemotherapy to hormonal and radiation therapy is feasible and is accepted by most @entity1 when they are openly informed of their prognosis with conventional therapy. Results in the current small series appear excellent and may be superior to radiation plus hormones alone. Larger randomized studies are warranted.
